This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Allogene Therapeutics, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Eric Hans Gschweng: Innovator in Therapeutic Cell Protection
Introduction
Eric Hans Gschweng is a notable inventor based in Oak Park, CA (US). He has made significant contributions to the field of therapeutic cell protection, holding a total of 2 patents. His work focuses on innovative solutions to enhance the efficacy of therapeutic cells in medical applications.
Latest Patents
Gschweng's latest patents include groundbreaking research on FASL expression and FASR gene knockout. This work aims to protect therapeutic cells from allogeneic rejection and activation-induced cell death. Additionally, he has developed methods for the knockdown or knockout of specific genes, such as TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP, and RFXANK, to mitigate T cell recognition of allogeneic cell products.
Career Highlights
Eric Hans Gschweng is currently associated with Allogene Therapeutics, Inc., where he continues to advance his research in the field. His innovative approaches have the potential to transform therapeutic strategies and improve patient outcomes.
Collaborations
Gschweng collaborates with esteemed colleagues, including Michael Thomas Bethune and Thomas John Van Blarcom. Their combined expertise fosters a dynamic research environment that drives innovation in therapeutic cell applications.
Conclusion
Eric Hans Gschweng is a prominent figure in the realm of therapeutic cell protection, with a focus on innovative gene editing techniques. His contributions are paving the way for advancements in medical therapies that could significantly benefit patients in need.